Drug Trial Radar · NCT07920185
A Study of Oral SOM001 as a Safe and Effective Treatment for Adults With Chronic Insomnia
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Feb 1, 2027
Primary completion
Oct 1, 2027
Study completion Feb 1, 2028
Sponsor
- Lead sponsor
- Somnum Pharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 5, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if SOM001 is safe and well tolerated in adults with insomnia. It will also evaluate if it helps to improve sleep. The main questions this trial aims to answer are: 1. Is SOM001 associated with any side-effects 2. Do people tolerate SOM001 well 3. Is SOM001 helpful to improve sleep Researchers will compare SOM001 to a placebo (a look-alike substance that contains no drug) as well as to 2 other well-established medications that are often used to treat sleep. Participants will: 1. Take one of the drugs, or placebo for 3 nights each week, for 3 weeks. The drugs will be pre-assigned and change each week. 2. Be asked questions about their sleep and overall health, including mental health 3. Complete tests to evaluate their memory and alertness on the computer 4. Use monitors at night to evaluate their sleep quality and activity. This will be a virtual study and participants will connect with the study team via video and phone calls for training and check-ups during the study.
Conditions
- Chronic Insomnia
Interventions
Low Dose Drug ADrug
Low Dose Drug A
Low Dose Drug BDrug
Low Dose Drug B
High Dose Drug ADrug
High Dose Drug A
High Dose Drug BDrug
High Dose Drug B
SOM001-ADrug
SOM001-A
SOM001-BDrug
SOM001-B
SOM001-CDrug
SOM001-C
SOM001-DDrug
SOM001-D
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with treatment-related adverse events at 3 weeks after SOM001 intervention as compared to placeboTime frame: 3 weeks
- Incidence, severity, and relationship of adverse events (AEs) after SOM001 intervention as compared to placeboTime frame: 3 weeks
- Incidence of serious adverse events (SAEs) after SOM001 intervention as compared to placeboTime frame: 3 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
4 East 70th Street, 9a
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.